Which of the following statements is accurate regarding anti-inflammatory drugs that are cyclooxygenase 2 (COX-2) selective?

Choice A rationale Celecoxib is a selective COX-2 inhibitor, meaning it primarily inhibits the cyclooxygenase-2 enzyme. COX-2 is induced at sites of tissue injury and inflammation, mediating the synthesis of pro-inflammatory prostaglandins. By selectively blocking COX-2, Celecoxib reduces inflammation and pain while potentially sparing the protective effects of the constitutively expressed COX-1 enzyme in the gastric mucosa, offering a lower risk of gastrointestinal side effects compared to non-selective NSAIDs. Choice B rationale COX-2 inhibitors, such as Celecoxib, are categorized as second-generation Nonsteroidal Anti-inflammatory Drugs (NSAIDs). First-generation NSAIDs, like ibuprofen and naproxen, are non-selective, inhibiting both the COX-1 and COX-2 isoenzymes. The development of COX-2 selective agents was a later pharmacological advancement aimed at improving the gastrointestinal safety profile. Choice C rationale COX-2 inhibitors were developed specifically to reduce the risk of peptic ulcers and gastrointestinal bleeding compared to non-selective NSAIDs. The COX-1 enzyme is responsible for synthesizing prostaglandins that maintain the protective gastric mucous layer and regulate gastric acid secretion. COX-2 selectivity aims to preserve these protective COX-1 functions. Choice D rationale COX-2 inhibitors work by reducing inflammation. They achieve this by selectively blocking the cyclooxygenase-2 enzyme, which is responsible for the increased synthesis of inflammatory prostaglandins at the site of tissue injury. Inhibiting this pathway reduces the cardinal signs of inflammation, including pain, swelling, and redness.